Traws Pharma, Inc.
corporate_fare Company Profile
Traws Pharma, Inc. (NASDAQ:TRAW) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 33 items for TRAW at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for TRAW spans 10-Q, 8-K, S-1, DEF 14A.
Recent high-impact activity:
- Traws 10-Q: $2.3M Cash, Going Concern Doubt, 35.5M Warrant Overhang
- Traws Pharma Posts Q3 Loss, $2.3M Cash; TXM Resubmission Set for Q4
- Traws Reports Final Phase 2a Ratutrelvir Data, Plans FDA Talks on PAXLOVID-Ineligible Path
- Traws Registers Resale of 135.1M Shares Behind $50M Roth Equity Line
- Traws Pharma Signs $50M Equity Line With Roth Principal Investments
Financial Snapshot
Short Interest & Short Volume
4.14 days to coverFINRA reported short interest of 683,674 shares in TRAW as of the October 30, 2026 settlement, a 0.3% decrease from the prior period — about 4.1 days to cover at its recent average daily volume. On November 20, 2026, 46.0% of TRAW volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for TRAW, detected from its recent SEC filings · based on capital-structure filings through 2026-10-26.
ATM Program Launched · Dilution Impact
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →